HMGB1 and neoplasm: Given that MP9 and its conjugates induced ICD by releasing DAMPs like HMGB1, ATP and CRT, the potential of the PEG-MP9-aPDL1 peptide-polymer conjugate to induce a tumor immunotherapeutic response in vivo was investigated following systemic administration in CT26 tumor bearing female BALB/c mice.